Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis

Reference

• Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.
   PubMed Web of Science ®Google Scholar
• Benson A, D’Angelica MI, Abbott DE, et al. National Comprehensive Cancer Network. Hepatobiliary cancers (version 2). Fort Washington (PA): National Comprehensive Cancer Network®; 2018. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Yu JJ, Yan WT, Quan B. Recommendations for EASL clinical practice guidelines: management of hepatocellular carcinoma. J Clin Hepatol. 2018;34(6):1183–1186.
   Google Scholar
• Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012;6:207–219.
   PubMedGoogle Scholar
• Wang XW, Fu SZ, Dai F, et al. The curative effect and safety in treating primary hepatocellular carcinoma: comparison between TACE plus radiofrequency ablation and TACE plus microwave ablation. J Intervent Radiol. 2016;25(8):673–676.
   Google Scholar
• Yuan P, Zhang ZG. K J. Analysis of efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. J Buon. 2019;24(1):164–170.
   Web of Science ®Google Scholar
• Shen Z, Yan H. Efficacy and safety of high-power microwave ablation combined with transcatheter arterial chemoembolization in interventional treatment of large liver cancer. Med Pharm J Chin PLA. 2016;28(10):31–35.
   Google Scholar
• Ginsburg M, Zivin SP, Wroblewski K, et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol. 2015;26(3):330–341.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. Br Med J. 2009;339:b2535–b2535.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Wells GA, Shea BJ, O’Connell D, et al. The Newcastle–Ottawa Scale (nos) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2014;18(6):727–734.
   Google Scholar
• Atkins D, Best D, Briss PA, et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328(7454):1490.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• Yue JY, Li YX, Wang QH, et al. Comparison on therapeutic effect between TACE combined with radiofrequency ablation and TACE combined with psychro-circulation percutaneous microwave coagulation therapy for primary hepatocellular carcinoma. Chin J Terv Imaging Ther. 2010;7(6):656–659.
   Google Scholar
• Vasnani RJ, Ginsburg M, Ahmed O, et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. Hepatobiliary Surg Nutr. 2016;5(3):225–233.
   PubMed Web of Science ®Google Scholar
• Sheta E, El-Kalla F, El-Gharib M, et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. Eur J Gastroenterol Hepatol. 2016;28(10):1198–1203.
   PubMed Web of Science ®Google Scholar
• Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2017;18(1):189–194.
   PubMedGoogle Scholar
• Thornton LM, Cabrera R, Kapp M. Radiofrequency vs microwave ablation after neoadjuvant transarterial bland and drug-eluting microsphere chembolization for the treatment of hepatocellular carcinoma. Curr Probl Diagn Radiol. 2017;46(6):402–409.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma L, Sheng SP, et al. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer. Minim Invasive Ther Allied Technol. 2018;27(6):355–364.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Habib A, Desai K, Hickey R, et al. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol. 2015;12(8):481–489.
   PubMed Web of Science ®Google Scholar
• Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89(6):1245–1251.
   PubMed Web of Science ®Google Scholar
• Tan WC, Deng QW, Lin SY, et al. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2019;36(1):264–272.
   PubMed Web of Science ®Google Scholar
• Poggi G, Montagna B, DI Cesare P, et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res. 2013;33:1221–1227.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y, Yu XL, et al. Malignant liver tumors: treatment with percutaneous microwave ablation-complications among cohort of 1136 patients. Radiology. 2009;251(3):933–940.
   PubMed Web of Science ®Google Scholar